Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.89 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | BTK | Q06187 | 2/20 | 0.71 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.70 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | TEK | Q02763 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861430 | 0.94 | PTGS1 (1.00) | PTGS1MAPTBTKKCNK3P2RX1 | |
| SCHEMBL549108 | 0.90 | MAPT (0.73) | PTGS1MAPTBTKKCNK3P2RX1 | |
| SCHEMBL15846979 | 0.90 | KCNK3 (0.79) | PTGS1MAPTBTKKCNK3P2RX1 | |
| SCHEMBL4286068 | 0.90 | MAPT (0.94) | PTGS1MAPTKCNK3P2RX1LMNA | |
| SCHEMBL6559364 | 0.87 | PTGS1 (1.00) | PTGS1MAPTKCNK3P2RX1LMNA | |
| SCHEMBL11307930 | 0.87 | PTGS1 (0.76) | PTGS1MAPTKCNK3P2RX1LMNA | |
| SCHEMBL22065212 | 0.86 | PTGS1 (0.80) | PTGS1MAPTBTKKCNK3P2RX1 | |
| SCHEMBL4476633 | 0.86 | MAPT (0.86) | PTGS1MAPTBTKKCNK3P2RX1 | |
| SCHEMBL6430912 | 0.86 | MAPT (0.81) | PTGS1MAPTKCNK3P2RX1LMNA | |
| SCHEMBL4683413 | 0.85 | KCNK3 (0.88) | PTGS1MAPTKCNK3P2RX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | claimed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | claimed |
| EP-1919924-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-05-14 | — | — | EP | claimed |
| WO-2007022268-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | claimed |
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | XIAMEN UNIVERSITY (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-3663293-A1 | SUBSTITUTED PENTA- AND HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | Xiamen University (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-05-28 | — | — | US | disclosed |
| WO-2015144926-A1 | 2-AMINO-1-PHENYL-PYRROLO[3,2-B]QUINOXALINE-3-CARBOXAMIDE DERIVATES | Universität Zürich (CH) | 2015-10-01 | — | — | WO | disclosed |
| EP-2924039-A1 | 2-Amino-1-phenyl-pyrrolo[3,2-b]quinoxaline-3-carboxamide derivates | Universität Zürich (CH) | 2015-09-30 | — | — | EP | disclosed |
| EP-2924039-A1 | 2-Amino-1-phenyl-pyrrolo[3,2-b]quinoxaline-3-carboxamide derivates | Universität Zürich (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | disclosed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
| CN-101291938-A | Compounds and compositions as protein kinase inhibitors | IRM LLC THE SCRIPPS RES INST (BM) | 2008-10-22 | — | — | CN | disclosed |
| EP-1963327-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| EP-1919924-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007062805-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007022268-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | disclosed |
| EP-0735403-B1 | Liquid crystal orienting agent | JSR CORP (JP) | 2004-03-17 | — | — | EP | disclosed |
| US-5700860-A | Liquid crystal orienting agent | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1997-12-23 | — | — | US | disclosed |
| EP-0735403-A1 | Liquid crystal orienting agent | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | AURKC, PTK2B, FRK | PTGS1 3242/4885MAPT 1523/4885BTK 41/4885 |
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | PIKFYVE, PIK3CA, PIK3C2A | PTGS1 3681/4885MAPT 2459/4885BTK 594/4885 |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | PIKFYVE, PIK3CA, PIK3C2A | PTGS1 3681/4885MAPT 2459/4885BTK 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.